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Perioperative aspirin and long-term 
survival in patients undergoing 
coronary artery bypass graft
Qian Ding1,2, Hong Liu3, Zugui Zhang4, Jordan Goldhammer1, Eric Yuen5, Zhongmin Li6, 
Linong Yao2, Nilas Young7, Douglas Boyd7, William Weintraub4, Rohinton Morris8 & 
Jianzhong Sun1
This study aimed to examine association between perioperative uses of aspirin and long-term survival 
in patients undergoing CABG. A retrospective cohort study was performed in 9,584 consecutive patients 
receiving cardiac surgery from three tertiary hospitals. Of all the patients, 4,132 patients undergoing 
CABG met inclusion criteria and were divided into four groups: with or without preoperative or 
postoperative aspirin respectively. 30-day postoperative and long-term mortality were compared with 
the use of propensity scores and inverse probability weighting adjustment to reduce the treatment-
selection bias. The patients taking preoperative aspirin presented significantly more with comorbidities. 
However, the results of this study showed that preoperative aspirin (vs. no preoperative aspirin) was 
associated with significantly reduced the risk of 30-day mortality in the patients undergoing CABG. 
Further, the results of long-term mortality showed that the patients taking preoperative aspirin and 
postoperative aspirin (vs. not taking) were associated with significantly reduced the risk of 4-year 
mortality (14.8% vs. 18.1%, RR: 0.82, 95% CI: 0.75–0.89, P = 0.005; 10.7% vs. 16.2%, RR: 0.66, 95% 
CI: 0.50–0.82, P = 0.003). In conclusion, this cohort study showed that perioperative (before and after 
surgery) use of aspirin was associated with significant reduction in 30-day mortality without significant 
bleeding complications, also improved long-term survival in patients undergoing CABG.
Aspirin is one of the most common used drugs in preventing and treating cardiovascular disease (CVD) and its 
complications. In 2002, Antiplatelet Trialists’ Collaboration led by Baigent et al., a meta-analysis on about 287 tri-
als (n = 212,000), has demonstrated that aspirin significantly reduced rates of myocardial infarction (MI), stroke 
and vascular mortality among the high-risk patients (secondary prevention) for long term use1. Concerning 
aspirin use in patients with CABG, however, the outcome results from randomized clinical trials (RCTs) and 
observational studies have been mixed and inconsistent2–4. Several meta-analyses in the area have showed that 
preoperative aspirin reduced perioperative MI, but was associated with an increased risk of reoperation, transfu-
sion and bleeding. However, these meta-analyses were based upon early RCTs that were small and underpowered 
for efficacy outcomes2–4. The observational studies in the area showed that preoperative aspirin was associated 
with a decreased risk of perioperative complications and death, with or without an increased risk of bleeding5–9. 
In 2011, the American Heart Association and American College of Cardiology (AHA/ACC) recommended that 
aspirin (100 mg-325 mg daily) should be administered to CABG patients preoperatively10, although conflicting 
guidelines existed concerning preoperative aspirin and cardiac surgery11,12. In 2016, a large RCT led by Myles 
et al. showed that among 2,100 patients undergoing CABG with or without valve surgery, preoperative aspirin 
(100 mg) given on the day of surgery did not reduce risk of primary outcome including 30-day death, MI, stroke, 
renal failure, pulmonary embolism or bowel infarction, nor did increase the risk of bleeding13.
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The length of follow-up is one of major limitations in most previous studies in the area of aspirin effects on 
cardiac surgery. Moreover, it remains unknown about perioperative aspirin’s effect on the long-term survival 
in patients undergoing CABG surgery. Thus far, a few studies have showed that aspirin started before or after 
surgery, improved vein graft patency up to 1 year after CABG14–16. Thus, this study aimed to examine association 
between perioperative (before and after surgery) use of aspirin and long-term survival in patients undergoing 
CABG.
Results
Characteristics of the study patients. Among 4132 included patients, 76.5% received preoperative aspi-
rin (PreASA), 23.5% did not (no-PreASA), 92.3% received postoperative aspirin (PostASA) and 7.7% did not 
(no-PostASA) respectively (Fig. 1). The patients’ demographic and clinical data are presented in Table 1. Before 
adjusted with using IPW, more patients taking aspirin than not taking one had smoking, diabetes, peripheral vas-
cular disease, angina, hypertension, previous MI, required urgent surgery and underwent CABG, but less under-
went CABG + valve surgery and took shorter time on bypass and cross-clamp; they were more with family history 
of CAD, more taking lipid lowering drugs, ACE inhibitors or beta blockers, but less with history of congestive 
heart failure, bypass time and cross clamp time. After adjustment with IPW, most of clinical covariates were well 
balanced and no significant differences were found between the two groups (Table 1). Figure 2 showed the pro-
pensity scores distribution between two groups, illustrating that patients taking preoperative aspirin had a higher 
probability of being selected for taking preoperative aspirin than those not taking aspirin. The mean, median and 
interquartile range of the propensity scores for preoperative aspirin reflected these differences (PreASA group: 
mean, 80.3%, median, 84.4%; interquartile range, 74.5% to 90.4%; No-PreASA group: mean, 64.0%, median, 
67.1%; interquartile range, 49.4% to 74.5%).
Preoperative aspirin, 30-day and long-term mortality. Of 4132 patients included in this study, 3161 
and 971 patients took or did not take preoperative aspirin, and showed 30-day mortality of 3.01% with PreASA and 
4.74% without PreASA, respectively. We used multivariate analyses to assess independent risk factors for 30-day 
mortality, and found that preoperative aspirin was associated with the reduced incidence of mortality (OR 0.707, 
95% CI 0.559–0.894, P < 0.01). As the value of C statistic showed, the multivariate regression analysis for preopera-
tive aspirin, achieved an acceptable discrimination between two groups (C = 0.747; 95% CI: 0.729–0.765; P < 0.001).
The mean, median, and interquartile range of the follow-up time for 4132 patients were 4.49 years, 3.77 years, 
and 1.39 to 7.16 years, respectively. Figure 3A,B showed unadjusted and adjusted survival curves in patients 
taking or not taking preoperative aspirin respectively. At 1 year, a significant difference was found in adjusted 
mortality between the groups (7.25% in preoperative aspirin group vs. 8.35% without preoperative aspirin group; 
RR, 0.87; 95% CI, 0.80 to 0.94). The survival benefits were also seen from preoperative 2-year to 4-year mortality 
changes. The adjusted 4-year mortality was 14.83% in preoperative aspirin group vs. 18.06% without preoperative 
aspirin group (RR, 0.82; 95% CI, 0.75 to 0.89).
Figure 1. Study population recruitment summary. ADP, adenosine diphosphate; CABG, Coronary Artery 
Bypass Grafting.
www.nature.com/scientificreports/
3Scientific RePoRtS |         (2018) 8:17051  | DOI:10.1038/s41598-018-35208-7
Postoperative aspirin and long-term survival. Based on discharge prescriptions after surgery, 3972 
patients were divided into two groups: those prescribed (3665) or not prescribed (307) postoperative aspirin 
(Fig. 1). The follow-up time for those 3972 patients was the same as preoperative aspirin (4 years on average). 
Overall, use of postoperative aspirin is associated with significant beneficial effects on long-term survival. 
Figure 4A,B showed unadjusted and adjusted survival curves in patients prescribed or not prescribed postoper-
ative aspirin respectively. At 1 year, a significant difference was found in adjusted mortality between the groups 
(3.16% in postoperative aspirin group vs. 9.77% without postoperative aspirin group; RR, 0.32; 95% CI, 0.26 to 
0.38). This survival benefit continued throughout 4-years follow-up. The adjusted 4-year mortality was 10.66% 
in postoperative aspirin group vs. 16.19% without postoperative aspirin group (RR, 0.66; 95% CI, 0.50 to 0.82).
The average adjusted hazard ratio and effect of unmeasured confounding. With the use of the 
Cox model analysis, the estimated average covariate-adjusted hazard ratio with preoperative aspirin as compared 
with non-preoperative aspirin was 0.801 (95% CI: 0.742–0.860, p-value = 0.017), slightly larger than the estimated 
4-year risk ratio (0.78) with obtained with wider 95% CI (0.71–0.85) via the use of IPW approach. Similarly, for 
postoperative aspirin as compared with non-postoperative aspirin, the estimated average covariate-adjusted haz-
ard ratio was 0.643 (95% CI: 0.58–0.71).
The impact of an unmeasured confounding is shown in Fig. 5. We used the X-axis to denote the assumed prev-
alence of the unmeasured confounder in the preoperative aspirin patients, and the Y-axis to denote the assumed 
hazard ratio for mortality related to this binary risk factor. We considered the assumed prevalence of the binary 
unmeasured confounder in non-preoperative at 5%, 10%, 20%, 30%, and 40%, respectively; and then we calcu-
lated corresponding hazard ratio related to the unmeasured confounder to explain the observed decreased risk. 
For instance, if an unmeasured binary risk factor was shown in 20% of the non-preoperative aspirin (blue curved 
line) and in 20%, 40%, or 60% of the preoperative aspirin, then using the method by Lin. et al.17 we obtained the 
hazard ratios for the unmeasured confounder to explain the observed decreased risk with non-preoperative aspi-
rin would be 5.83, 4.17, and 2.08, respectively.
Discussion
The results of this cohort study showed that preoperative and postoperative aspirin therapy was associated with 
a significant long-term survival benefit among the patients undergoing CABG. In addition, preoperative aspirin 
was associated with a reduced risk of postoperative 30-day mortality without increased bleeding complications9 
in patients undergoing CABG. Overall, the findings reveal that benefits of perioperative uses of aspirin exceed 
Characteristic
Unadjusted Data
P Value
Adjusted Data (IPW)
P 
Value
PreASA 
(N = 3161)
no-PreASA 
(N = 971)
PreASA 
(N = 3161)
no-PreASA 
(N = 971)
Age, mean (SD), y 66.3 (10.8) 64.1 (13.6) <0.001 66.0 (12.6) 66.8 (25.1) 0.072
Male sex, % 79.0 70.1 <0.001 49.1 49.7 0.595
BMI, mean (SD), kg/m2 29.1 (6.0) 28.8 (6.0) 0.143 29.1 (6.9) 29.3 (12.7) 0.188
Diabetes, % 39.0 29.4 <0.001 37.1 40.5 0.001
Smoker, % 42.1 38.1 0.026 41.7 44.1 0.031
Hypertension, % 84.2 70.7 <0.001 81.5 83.2 0.042
Cerebrovascular disease, % 15.3 15.0 0.816 15.4 17.4 0.016
Peripheral vascular disease, % 14.4 10.9 0.005 13.9 15.6 0.033
Chronic lung disease, % 20.5 18.9 0.252 20.1 20.8 0.438
Family history CAD, % 47.5 33.6 <0.001 44.2 46.4 0.046
Creatinine, mean (SD), mg/dl 1.2 (1.1) 1.3 (1.3) 0.132 1.3 (1.3) 1.3 (2.3) 0.826
Angina, % 46.6 30.3 <0.001 42.9 42.4 0.630
Congestive heart failure, % 22.3 32.5 <0.001 24.9 24.3 0.460
Previous MI, % 37.9 26.9 <0.001 35.3 35.9 0.570
Beta blockers, % 77.0 50.0 <0.001 70.7 71.5 0.427
ACE inhibitors or ARB, % 42.8 33.1 <0.001 41.1 42.2 0.311
Lipid lowering, % 65.3 44.4 <0.001 60.5 61.5 0.361
Urgent status, % 54.3 44.6 <0.001 51.9 49.8 0.061
Initial ICU Hours 92.4 (127.5) 104.9 (137.0) 0.01 94.5 (151.6) 99.2 (257.9) 0.240
CABG, % 83.8 71.3 <0.001 80.5 79.7 0.353
CABG and Valve, % 16.2 28.7 <0.001 19.5 20.3 0.353
Cardiopulmonary Bypass Time (SD), min 118.5 (73.8) 143.4 (92.6) <0.001 124.6 (91.9) 123.7 (171.8) 0.781
Cross Clamp Time (SD), min 85.8 (55.2) 100.2 (66.4) <0.001 89.2 (66.1) 89.0 (128.2) 0.934
Table 1. Demographic and Clinical Characteristics of Patients (PreASA). BMI, body mass index, is the weight 
in kilograms divided by the square of the height in meters; MI, myocardial infarction; CAD, coronary artery 
disease; ACE, angiotensin-converting enzyme; ARB, Angiotensin Receptor Blockers; CABG, Coronary Artery 
Bypass Grafting; SD, standard deviation.
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hazards in patients undergoing CABG, in particular, perioperative uses of aspirin showed a strong association 
with improved long-term survival in the real world practice.
In the area of the research on aspirin and cardiac surgery, it is still uncertain and controversial about aspirin’s 
effects in patients with CABG, partially because it has been lacking of the hard-endpoint result–long term mor-
tality. It was difficult to appreciate the overall picture of aspirin’s effects on cardiac surgery patients due to lacking 
Figure 2. Propensity Scores for Preoperative Aspirin in Patients undergoing Coronary Artery Bypass Grafting 
(CABG) Surgery. The propensity score for Preoperative Aspirin is the probability given baseline variables that 
any patient in either group would take aspirin before cardiac surgery.
Figure 3. Rates of Survival in patients with preoperative aspirin (PreASA) or no-preoperative aspirin (no-
PreASA). (A) From an un-adjusted Analysis. (B) From an analysis adjusted with the use of Inverse Probability 
Weighting (IPW). The inset shows the same data on an enlarged y axis. (C) Cumulative mortality with and 
without preoperative aspirin, and the relative risk of PreASA as compared with no-PreASA are shown.
www.nature.com/scientificreports/
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Figure 4. Rates of survival in patients with postoperative aspirin (PostASA) or no-postoperative aspirin (no-
PostASA). (A) From an un-adjusted Analysis. (B) From an analysis adjusted with the use of Inverse Probability 
Weighting (IPW). The inset shows the same data on an enlarged y axis. (C) Cumulative mortality with and 
without postoperative aspirin, and the relative risk of PostASA as compared with no-PostASA are shown.
Figure 5. The average adjusted hazard ratio and effect of unmeasured confounding. The impact of unmeasured 
confounding factors on the hazard ratio has been one of the crucial uncertainties. Figure 5 shows the impact of a 
single confounder on the benefits of preoperative aspirin over without preoperative aspirin detected in the IPW 
adjusted analysis. If a single unmeasured confound could increase the long-term risk of mortality by a factor or 
about 1.7 or if the long-term mortality rate was two to six times as high among the preoperative aspirin patients 
as in the non-preoperative aspirin patients, it could generate the observed survival differences. As we can see 
that if a potential confounder was present in 40% of the non-preoperative aspirin patients (red curved line) and 
in 60% of pre-operative aspirin (X-axis), and if it increased the mortality rate by a factor of about 1.7 (hazard 
ratio, 1.81), the confounder alone could constitute the observed difference in mortality between preoperative 
aspirin and non-preoperative aspirin patients.
www.nature.com/scientificreports/
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of clinical evidence: long-term survival. Previous clinical studies have clearly showed that the treatment effect 
on chronic CVD takes a long time to emerge. For example, early clinical studies of vein grafts have shown that 
perioperative administration of aspirin improves the graft patency up to 12 month after the operation14–16. The 
SYNTAX18 and ASCERT19 trial demonstrated that the benefits of CABG vs PCI did not occur until 3–5 years later 
after the operation. The longitude of this study is extended from immediate postoperative time to an average of 
4-years. The results of the present study revealed that the treatment effect with preoperative aspirin regarding the 
primary outcome – the long term survival (15–20% improvement) was similar to that observed in Antiplatelet 
Trialists’ Collaboration1 and also other proven medical treatments20,21, indicating that aspirin is an effective drug 
in improving long-term survival of patients with CABG.
With regard to aspirin’s short term effects, a recent RCT, ATACAS trial13 showed that among patients under-
going CABG with or without valve surgery or another procedure, the administration of preoperative aspirin 
resulted in neither a lower risk of death or thrombotic complications nor a higher risk of bleeding than that with 
placebo. The absence of an adverse bleeding effect in this trial is in line with previous clinical studies5–9 adding 
new evidence that a low-dose aspirin does not have significant effect on bleeding in patients undergoing cardiac 
surgery. The study should be commended for their strength of randomization. Nonetheless, the hard end-point - 
the event rate of death in this study was very low: there were only 14 vs 9 deaths in the treated (n = 1047) and 
placebo (n = 1053) groups, indicating a low-risk cohort of patients included in the study.
The beneficial effects of aspirin, in particular, its anti-inflammatory and/or pleiotropic effects most likely take 
time to occur. On this front, recent studies on potential mechanisms for aspirin in preventing atherothrombosis 
and chemoprevention on cancer have showed that, apart from suppressing thromboxane (TX) A2 production and 
TXA2-mediated platelet activation and aggregation, aspirin may play its multifaceted clinical effects via acetylat-
ing proteins in blood coagulation, inhibiting COX-2 activity and a variety of COX-independent mechanisms22. 
The underlying rationale for this study was that aspirin, for the long-term use, would prevent events related to its 
anti-inflammation and pleiotropic effects, in addition to those related to anti-platelet and anti-thrombosis.
The present study provided additional findings regarding effects of preoperative aspirin, including the associ-
ation with reducing 30-day mortality without significant bleeding complications; the findings complement those 
of previous studies5–9,23. In addition, in a separate study9, we examined preoperative aspirin and bleeding com-
plications in patients undergoing cardiac surgery. The results showed that preoperative aspirin did not signifi-
cantly increase bleeding complications, including chest tube drainage, reoperation for bleeding. As it is known, 
CABG surgery frequently provokes an extreme and complex stress and hypercoagulable state, with an increased 
predisposition to long-term vascular morbidity and mortality. Perioperative aspirin may provide cardiovascular 
protection with potential short- and long-term benefits for survival.
Limitations of this study. First, we have applied the propensity scores, IPW and other methods in this 
study to minimize biases and control confounding, however, the potential flaws of a non-randomized study may 
still exist. Second, other unknown confounding factors may exist which could affect the outcomes, thus we did an 
analysis as described in Fig. 5. With regard to longitudinal data and/or survival analysis, we selected the method 
of IPW due to its advantages in the analysis in comparison with the methods of matching and stratification24,25. 
Third, clinically it would be appropriate to group the patients based on whether they were taking aspirin during 
both the pre- and post-operative period (continuing aspirin) compared with patients they were not on aspirin at 
any point during the perioperative period (no aspirin). However, a timespan of the cohort follow-up between pre-
operative aspirin and postoperative aspirin prescription is “immortal” since exposed patients who received their 
first prescription (preoperative aspirin) had to survive until their second prescription (postoperative aspirin), 
which introduces an immortal time. Thus, classifying aspirin into 2 groups (continuation vs. none) has a prob-
lem due to the difference exposure (immortal time bias) of the groups26. Fourth, we lacked data on the dose and 
adherence of aspirin in this cohort of patients (due to lack of refill records and aspirin being an over-the-counter 
drug). However, the discharge prescription of aspirin often is indicated for patients with CABG and it should be 
continued indefinitely and the usual doses are 81 mg–325 mg daily, except for ones with contraindications. In 
addition, the reported rates of patient aspirin adherence for cardiovascular protection are high, range from 72% 
to 92% in the literature27. The association we found in this study suggests that perioperative aspirin may provide 
cardiovascular protection with potential long-term benefits for survival. The results of this study also indicate that 
further studies, including basic mechanistic studies and large clinical studies, both RCTs and pragmatic studies 
are still needed to assess aspirin effectiveness in patients undergoing cardiac surgery.
Conclusions
Among patients undergoing CABG, taking aspirin before and after surgery was associated with a significant 
reduced mortality risk during 4-years of follow-up.
Methods
Study design. A retrospective and cohort study was performed in patients (n = 9584) undergoing cardiac 
surgery at three teaching hospitals (Thomas Jefferson University hospital, Abington Memorial hospital and UC 
Davis Medical Center, dated from 2001 to 2015). The study was in accordance with the Declaration of Helsinki28, 
approved by the local Institutional Review Board (IRB) including Thomas Jefferson University IRB and UC 
Davis IRB, and individual consent was waived in compliance with the HIPAA regulations and the waiver cri-
teria. Preoperative and postoperative uses of aspirin are defined as within 5 days preceding surgery and on the 
discharge respectively. Of all patients, 4,132 patients undergoing CABG with or without valve surgery met the 
inclusion criteria and were divided into four groups: with or without preoperative (within 5 days preceding sur-
gery) or postoperative (on discharge) aspirin respectively (Fig. 1).
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7Scientific RePoRtS |         (2018) 8:17051  | DOI:10.1038/s41598-018-35208-7
Data collection. The following data were collected: patient demographics, history, medical record infor-
mation, preoperative risk factors, preoperative medications, intraoperative data, postoperative 30-day all-cause 
mortality, discharge medicines and long-term all-cause mortality. For missing at completely random and low 
missing rate variables, missing data values will be imputed using multiple multivariate imputation by chained 
equations for continuous variables (to enhance prediction of the missing value, relevant variables were stratified), 
and the most frequent value for categorical variables. For missing at random, each missing value was replaced 
with multiple imputation procedure, which used a set of plausible values to impute19,29.
Measurement of Outcomes. Primary endpoints were 30-day and long-term mortality, which were 
based on the data Registry of our three hospitals and the Social Security Death Index30. The survival time 
(time-to-event) of the subject began when the subject had CABG, and ended when the end-point (the death) was 
reached or the subject was censored from the study31.
Adjustment for differences between groups. As anticipated, patients with or without preoperative or 
postoperative aspirin would differ significantly regarding baseline (before surgery) characteristics. Using multilevel 
logistic regression, a propensity score was derived on the patient characteristics, reflecting the probability that a 
patient would receive preoperative aspirin. The individual variables included in the propensity model are listed in 
Table 1. The inverse probability weighting (IPW) approach based on the propensity scores was then applied as the 
tool to adjust for differences between the groups32. The performance of propensity model was verified by comparing 
the distribution of covariates and propensity scores between groups both before and after the IPW33.
Statistical analysis. The Pearson chi-square test and Wilcoxon rank-sum test were used for analyzing continuous 
or categorical variables respectively. For long-term survival, survival curves were estimated with using the Kaplan-Meier 
method (unadjusted)34, then re-estimated with using the IPW approach (adjusted) by Cole and Hernan35. For each 
group with or without preoperative or postoperative aspirin, the survival curves adjusted with the use of IPW represent 
the expected rate of survival if the treatment of interest were applied to all study patients. Risk ratios at specific time 
points were calculated with estimated rates of survival among patients receiving CABG with or without preoperative 
and postoperative aspirin, 95% confidence intervals were obtained with bootstrap methods.
To conduct sensitivity analysis, survival curves were re-estimated separately for patients with or without pre-
operative and postoperative aspirin with the use of Cox proportional-hazard models without propensity scores36. 
The same covariates were used in each model as those used in the propensity model above. Further, to examine 
the impact of potential unmeasured confounders, we conducted covariate-adjusted Cox modelling to estimate 
average hazard rations for preoperative aspirin group vs. non-preoperative aspirin, as well as post-operative aspi-
rin vs. non-aspirin. Additionally, we evaluated if the observed differences in the mortality rate could be thor-
oughly explained via an unmeasured confounder on the basis of the method outlined by Lin et al.17. Percentages, 
relative risk (RR), hazard ratio (HR), 95% confidence intervals (CI) and P values (2-sided) <0.05 were given 
in the results. SAS version 9.4 (SAS Institute, Inc, Cary, NC) and SPSS 17.0 software for Windows (SPSS Inc., 
Chicago, IL) were used for the statistical analysis.
Data Availability
All data generated or analyzed in this study are available from the corresponding author on reasonable request.
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